A dual cannabinoid agonist drug candidate is being investigated for its potential in treating wasting syndrome in cancer patients. It demonstrated a weight gain in patients who took the drug versus a ...

New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle regulation theory" of cancer-induced cachexia and anorexia. Cachexia is a ...

Cancer dominates the drug development pipeline, but industry has paid little attention over the years to cancer cachexia — the complex weight-loss syndrome that accounts for 20–30% of cancer deaths.

Cancer cachexia robs patients of weight, muscle, and strength, undermining treatment success and quality of life. Experts now advocate for a multimodal approach—combining nutrition, exercise, and ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Cancer ravages both body and mind. If you've ever lost loved ones to the disease, you might recognize the physical and emotional changes cancer patients often endure during their final months. They ...

"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Moffitt researchers, with patience at the forefront, tackle a difficult issue that, undetected, makes treating cancer more difficult.